🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

The sexually transmitted infection are increasing around the world, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This authorization signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

Based on data released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which involves a dual-drug approach. The trial involved over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals treating patients have voiced optimism. Access to a easy-to-administer therapy of this kind is described as a "critical tool" for public health efforts. This is considered crucial to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.